Homepage > Company > Media > Pharma News > 2021 > FDA waves through J&J's targeted drug Rybrevant for subset of NSCLC patients

FDA waves through J&J's targeted drug Rybrevant for subset of NSCLC patients

The FDA on Friday approved Johnson & Johnson's marketing application for Rybrevant (amivantamab-vmjw), making it the first targeted treatment option for adult patients with non-small-cell lung cancer (NSCLC) whose tumours have EGFR exon 20 insertion mutations. Rybrevant, also known as JNJ-61186372, is a bispecific antibody with immune cell-directing activity against both EGFR- and MET-driven disease.

"Advances in precision oncology continue to facilitate drug development, allowing diseases like lung cancer to be subset into biomarker-defined populations appropriate for targeted therapies," remarked Julia Beaver, acting deputy director of the Office of Oncologic Diseases in the FDA's Center for Drug Evaluation and Research.

May 21st, 2021

https://www.firstwordpharma.com/

Read also

Spinogenix’s ALS hopeful to advance to registrational trial

Spinogenix’s first-in-class ALS treatment, SPG302 has been shown to slow disease progression in 82% of patients during a Phase IIa study.

FDA Approves First Treatment for Rare Thymidine Kinase 2 Deficiency

Thymidine kinase 2 deficiency (TK2d) is an ultra-rare (1.64 cases per 1,000,000 people) often fatal, genetic mitochondrial disease characterized by progressive and severe muscle weakne...

Cencora

Cencora to invest $1bn in US pharma distribution network

Celltrion

Celltrion Signs Licensing Deal with U.S. Kaigene for Two Antibody Drug Candidates